瑞银：中国 CRO _ 生物制药调查_业务拓展（BD）、研发预算和外包率上升将使 CRO_CDMO 受益

ab 10 June 2025 Powered by YES UBS Evidence Lab Global Research China CRO Sector Biopharma survey: the rising BD, R&D budget and outsourcing rate to benefit CRO/CDMO Wave 2 survey points to rising BD activities and R&D budget UBS Evidence Lab conducted the second wave of the China Biopharma Executive Survey (first wave in 2024), to gauge the biopharma industry's attitude to obtaining further funding, expanding R&D and investment, as well as their willingness to outsource R&D to contract research/development ...